CA2348993C - Substituted phenethylsulfones and method of reducing tnf.alpha. levels - Google Patents

Substituted phenethylsulfones and method of reducing tnf.alpha. levels Download PDF

Info

Publication number
CA2348993C
CA2348993C CA002348993A CA2348993A CA2348993C CA 2348993 C CA2348993 C CA 2348993C CA 002348993 A CA002348993 A CA 002348993A CA 2348993 A CA2348993 A CA 2348993A CA 2348993 C CA2348993 C CA 2348993C
Authority
CA
Canada
Prior art keywords
sulfone
ethoxy
hydrogen
methoxyphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002348993A
Other languages
French (fr)
Other versions
CA2348993A1 (en
Inventor
Hon-Wah Man
George Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CA2348993A1 publication Critical patent/CA2348993A1/en
Application granted granted Critical
Publication of CA2348993C publication Critical patent/CA2348993C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Phenethylsulfones substituted .alpha. to the phenyl group with a 1- oxoisoindoline or 1,3-dioxoisoindoline reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 2-[1-(3-ethoxy-4-methoxyphenyl)-2- methylsulfonylethyl)-4-aminoisoindoline-1,3-dione.

Description

SUBSTITUTED PHENETHYLSULFONES AND
METHOD OF REDUCING TNFa LEVELS

The present invention relates to substituted phenethylsulfones substituted a to the phenyl group with a 1-oxoisoindoline group, the method of reducing levels of tumor necrosis factor a and treating inflammatory and autoimmune diseases in a mammal through the administration thereof, and to pharmaceutical compositions of such derivatives.

Background of the Invention Tumor necrosis factor a, or TNFa, is a cytokine which is released primarily by io mononuclear phagocytes in response to a number immunostimulators. When administered to animals or humans, it causes inflammation, fever, cardiovascular effects, hemorrhage, coagulation, and acute phase responses similar to those seen during acute infections and shock states. Excessive or unregulated TNFa production thus has been implicated in a number of disease conditions. These include endotoxemia and/or toxic shock syndrome {Tracey et al., Nature 330, 662-664 (1987) and Hinshaw et al., Circ. Shock 30, 279-292 (1990)); rheumatoid arthritis, Crohn's disease, IBD, cachexia {Dezube et al., Lancet, 335 (8690), 662 (1990)) and Adult Respiratory Distress Syndrome where TI`1Fa concentration in excess of 12.000 pg/mL
have been detected in pulmonary aspirates from ARDS patients {Millar et al..
Lancet 2o 2(8665), 712-714 (1989)). Systemic infusion of recombinant TNFa also resulted in changes typically seen in ARDS {Ferrai-Baliviera et al., Arch. Surg. 124(12), 1405 (1989)).

TNFa appears to be involved in bone resorption diseases, including arthritis.
When activated, leukocytes will produce bone-resorption, an activity to which the data suggest TNFa contributes. (Bertolini et al., Nature 319, 516-518 (1986) and Johnson et al., Endocrinology 124(3), 1424-1427 (1989)). TNFa also has been shown to stimulate bone resorption and inhibit bone formation in vitro and in vivo through stimulation of osteoblast formation and activation combined with inhibition of osteoblast function.
Although TNFa may be involved in many bone resorption diseases, including arthritis, a most compelling link with disease is the association between production of TNFa by tumor or host tissues and malignancy associated hypercalcemia {Calci. Tissue Int. (US) 46(Supp1.), S3-10 (1990)). In Graft versus Host Reaction, increased serum TNFa levels have been associated with major complication following acute allogenic bone marrow transplants {Holler et al., Blood, 75(4), 1011-1016 (1990)).

Cerebral malaria is a lethal hyperacute neurological syndrome associated with high blood levels of TNFa and the most severe complication occurring in malaria patients.
Levels of serum TNFa correlated directly with the severity of disease and the prognosis in patients with acute malaria attacks {Grau et al., N. Engi. J. Med. 320(24), (1989)).

Macrophage-induced angiogenesis is known to be mediated by TNFa. Leibovich et al. (Nature, 329, 630-632 (1987)) showed TNFa induces in vivo capillary blood vessel formation in the rat cornea and the developing chick chorioallantoic membranes at very low doses and suggest TNFa is a candidate for inducing angiogenesis in inflammation, wound repair, and tumor growth. TNFa production also has been associated with cancerous conditions, particularly induced tumors {Ching et al., Brit. J.
Cancer, (1955) 72, 339-343, and Koch, Progress in Medicinal Chemistry, 22, 166-242 (1985)).

TNFa also plays a role in the area of chronic pulmonary inflammatory diseases.
The deposition of silica particles leads to silicosis, a disease of progressive respiratory failure caused by a fibrotic reaction. Antibody to TNFa completely blocked the silica-induced lung fibrosis in mice {Pignet et al., Nature, 344:245-247 (1990)).
High levels of TNFa production (in the serum and in isolated macrophages) have been demonstrated in animal models of silica and asbestos induced fibrosis {Bissonnette et al., Inflammation 13(3), 329-339 (1989)). Alveolar macrophages from pulmonary sarcoidosis patients have also been found to spontaneously release massive quantities of TNFa as compared with macrophages from normal donors {Baughman et al., J. Lab.
Clin. Med. 115(1), 36-42 (1990)).

TNFa is also implicated in the inflammatory response which follows reperfusion, called reperfusion injury, and is a major cause of tissue damage after loss of blood flow l 0 (Vedder et al., PNAS 87, 2643-2646 (1990)). TNFa also alters the properties of endothelial cells and has various pro-coagulant activities, such as producing an increase in tissue factor pro-coagulant activity and suppression of the anticoagulant protein C
pathway as well as down-regulating the expression of thrombomodulin {Sherry et al., J. Cell Biol. 107, 1269-1277 (1988)). TNFa has pro-inflammatory activities which together with its early production (during the initial stage of an inflammatory event) make it a likely mediator of tissue injury in several important disorders including but not limited to, myocardial infarction, stroke and circulatory shock. Of specific importance may be TNFa-induced expression of adhesion molecules, such as intercellular adhesion molecule (ICAM) or endothelial leukocyte adhesion molecule (ELAM) on endothelial cells (Munro et al., Am. JPath. 135(1), 121-132 (1989)).

TNFa blockage with monoclonal anti-TNFa antibodies has been shown to be beneficial in rheumatoid arthritis {ElIiot et al., Int. J. Pharmac. 1995 17(2), 141-145) and Crohn's disease {von Dullemen et al., Gastroenterology, 1995 109(1), 129-135) Moreover, it now is known that TNFa is a potent activator of retrovirus replication including activation of HIV-1. {Duh et al., Proc. Nat. Acad. Sci. 86, 5.974-(1989); Poll et al., Proc. Nat. Acad. Sci. 87, 782-785 (1990); Monto et al., Blood 79, 2670 (1990); Clouse et al., J. Immunol. 142, 431-438 (1989); Poll et al., AIDS
Res.

Hum. Retrovirus, 191-197 (1992)). AIDS results from the infection of T
lymphocytes with Human Immunodeficiency Virus (HIV). At least three types or strains of HIV
have been identified; i.e., HIV-1, HIV-2 and HIV-3. As a consequence of HIV
infection, T-cell mediated immunity is impaired and infected individuals manifest severe opportunistic infections and/or unusual neoplasms. HIV entry into the T
lym-io phocyte requires T lymphocyte activation. Other viruses, such as HIV-1, HIV-2 infect T lymphocytes after T cell activation and such virus protein expression and/or replication is mediated or maintained by such T cell activation. Once an activated T
lymphocyte is infected with HIV, the T lymphocyte must continue to be maintained in an activated state to permit HIV gene expression and/or HIV replication.
Cytokines, specifically TNFa, are implicated in activated T-cell mediated HIV protein expression and/or virus replication by playing a role in maintaining T lymphocyte activation.
Therefore, interference with cytokine activity such as by prevention or inhibition of cytokine production, notably TNFa, in an HIV-infected individual assists in limiting the maintenance of T lymphocyte caused by HIV infection.

Monocytes, macrophages, and related cells, such as kupffer and glial cells, also have been implicated in maintenance of the HIV infection. These cells, like T
cells, are targets for viral replication and the level of viral replication is dependent upon the activation state of the cells. (Rosenberg et al., The Immunopathogenesis of HIV
Infection, Advances in Immunology, 57 (1989)). Cytokines, such as TNFa, have been shown to activate HIV replication in monocytes and/or macrophages {Poli et al., Proc.
Natl. Acad Sci., 87, 782-784 (1990)); therefore, prevention or inhibition of cytokine production or activity aids in limiting HIV progression for T cells.
Additional studies have identified TNFa as a common factor in the activation of HIV in vitro and has provided a clear mechanism of action via a nuclear regulatory protein found in the cytoplasm of cells (Osbom, et al., PNAS 86 2336-2340). This evidence suggests that a reduction of TNFa synthesis may have an antiviral effect in HIV infections, by reducing the transcription and thus virus production.

AIDS viral replication of latent HIV in T cell and macrophage lines can be induced by TNFa {Folks et al., PNAS 86, 2365-2368 (1989)). A molecular mechanism for the io virus inducing activity is suggested by 1NFa's ability to activate a gene regulatory protein (NFxB) found in the cytoplasm of cells, which promotes HIV replication through binding to a viral regulatory gene sequence (LTR) {Osbom et al., PNAS
86, 2336-2340 (1989)). TNFa in AIDS associated cachexia is suggested by elevated serum TNFa and high levels of spontaneous TNFa production in peripheral blood monocytes from patients {Wright et al., J. Immunol. 141(1), 99-104 (1988)).
TNFa has been implicated in various roles with other viral infections, such as the cytomegalia virus (CMV), influenza virus, adenovirus, and the herpes family of viruses for similar reasons as those noted.

The nuclear factor KB (NFxB) is a pleiotropic transcriptional activator (Lenardo, et al., Cell 1989, 58, 227-29). NFxB has been implicated as a transcriptional activator in a variety of disease and inflammatory states and is thought to regulate cytokine levels including but not limited to TNFa and also to be an activator of HIV
transcription (Dbaibo, et al., JBiol. Chem. 1993, 17762-66; Duh et al., Proc. Natl. Acad.
Sci. 1989, 86, 5974-78; Bachelerie et al., Nature 1991, 350, 709-12; Boswas et al., J
Acquired Immune Deficiency Syndrome 1993, 6, 778-786; Suzuki et al., Biochem. And Biophys.
Res. Comm. 1993, 193, 277-83; Suzuki et al., Biochem. And Biophys. Res. Comm.
1992, 189, 1709-15; Suzuki et al., Biochem. Mol. Bio. Int. 1993, 31(4), 693-700;
Shakhov et al., Proc. Natl. Acad. Sci. USA 1990, 171, 35-47; and Staal et al., Proc.

Natl. Acad Sci. USA 1990, 87, 9943-47). Thus, inhibition of NFxB binding can regulate transcription of cytokine gene(s) and through this modulation and other mechanisms be useful in the inhibition of a multitude of disease states. The compounds described herein can inhibit the action of NFxB in the nucleus and thus are useful in the treatment of a variety of diseases including but not limited to rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, cancer, septic shock, sepsis, endotoxic shock, graft versus host disease, wasting, Crohn's disease, inflammatory bowel disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, HIV, AIDS, and opportunistic infections in AIDS.
TNFa and NFxB levels are influenced by a reciprocal feedback loop. As noted above, the compounds of the present invention affect the levels of both TNFa and NFicB.

Many cellular functions are mediated by levels of adenosine 3',5'-cyclic monophosphate (cAMP). Such cellular functions can contribute to inflammatory conditions and diseases including asthma, inflammation, and other conditions (Lowe and Cheng, Drugs of the Future, 17(9), 799-807, 1992). It has been shown that the elevation of cAMP in inflammatory leukocytes inhibits their activation and the subsequent release of inflammatory mediators, including TNFa and NFxB.
Increased levels of cAMP also leads to the relaxation of airway smooth muscle.

The primary cellular mechanism for the inactivation of cAMP is the breakdown of cAMP by a family of isoenzymes refen-ed to as cyclic nucleotide phosphodiesterases (PDE) (Beavo and Reitsnyder, Trends in Pharm., 11, 150-155, 1990). There are seven known members of the family of PDEs. It is recognized, for example, that the inhibition of PDE type IV is particularly effective in both the inhibition of inflammatory mediator release and the relaxation of airway smooth muscle (Verghese, et al., Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995). Thus, compounds that inhibit PDE IV specifically, would exhibit the desirable inhibition of inflammation and relaxation of airway smooth muscle with a minimum of unwanted side effects, such as cardiovascular or anti-platelet effects. Currently used PDE
IV inhibitors lack the selective action at acceptable therapeutic doses. The compounds of the present l0 invention are useful in the inhibition of phosphodiesterases, particularly PDE III and PDE IV, and in the treatment of disease states mediated thereby.

Decreasing TNFa levels, increasing cAMP levels, and inhibiting PDE IV thus constitute valuable therapeutic strategies for the treatment of many inflammatory, infectious, immunological or malignant diseases. These include but are not restricted to septic shock, sepsis, endotoxic shock, hemodynamic shock and sepsis syndrome, post ischemic reperfusion injury, malaria, mycobacterial infection, meningitis, psoriasis, congestive heart failure, fibrotic disease, cachexia, graft rejection, cancer, autoimmune disease, opportunistic infections in AIDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, other arthritic conditions, Crohn's disease, ulcerative colitis, multiple sclerosis, systemic lupus erythrematosis, ENL in leprosy, radiation damage, and hyperoxic alveolar injury. Prior efforts directed to the suppression of the effects of TNFa have ranged from the utilization of steroids such as dexamethasone and pred-nisolone to the use of both polyclonal and monoclonal antibodies {Beutler et al., Science 234, 470-474 (1985); WO 92/11383).

Detailed Description The present invention is based on the discovery that certain classes of non-polypeptide compounds more fully described herein decrease the levels of TNFa.

In particular, the invention pertains to phenethylsulfone compounds of Formula I:
Rt \ / R6 N-CH

I
in which the carbon atom designated * constitutes a center of chirality;
Y is C=O, CH2, SO2, or CH2C=O;

to each of R', RZ, R', and R4, independently of the others, is hydrogen, halo, alkyl of I to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano, hvdroxy, or -NR8R9; or any two of R', RZ, R`, and R4 on adjacent carbon atoms, together with the depicted phenylene ring are naphthylidene;

each of RS and R6, independently of the other, is hydrogen, alkyl of I to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, or cycloalkoxy of up to 18 carbon atoms;

R' is hydroxy, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, or NR"R";

each of Rg and R9 taken independently of the other is hydrogen, alkyl of I to carbon atoms, phenyl, or benzyl, or one of Rg and R9 is hydrogen and the other is -COR10 or -SOZR'0, or Rg and R9 taken together are tetramethylene, pentamethylene, hexamethylene, or -CH2CH2X1CH2CH2- in which Xl is -0-, -S- or -NH-; and each of R8' and R9' taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R8' and R9' is hydrogen and the other is -COR10 or -SO2R10l , or Re and R9, taken together are tetramethylene, pentamethylene, hexamethylene, or -CH2CH2X2CH2CH2- in which X2 is -0-, -S-, or -NH-, R10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and Rlo' is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; or (b) the acid addition salts of said compounds which contain a nitrogen atom susceptible of protonation.
The term alkyl denotes a univalent saturated branched or straight hydrocarbon chain containing from I to 8 carbon atoms. Representative of such alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert.-butyl. Alkoxy refers to an alkyl group bound to the remainder of the molecule through an ethereal oxygen atom.
Representative of such alkoxy groups are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert.-butoxy.

The term cycloalkyl as used herein denotes a univalent cyclic hydrocarbon chain which may be saturated or unsaturated. Unless otherwise stated, such chains can contain up to 18 carbon atoms and include monocycloalkyl, polycycloalkyl, and benzocycloalkyl structures. Monocycloalkyl refers to groups having a single ring group.
Polycycloalkyl denotes hydrocarbon systems containing two or more ring systems with one or more ring carbon atoms in common; i.e., a spiro, fused, or bridged structure.
Benzocycloalkyl signifies a monocyclic alkyl group fused to a benzo group. Representative of monocycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentadecyl, cyclohexadecyl, cycloheptadecyl, and cyclooctadecyl.
Representative of polycycloalkyl include decahydronaphthalene, spiro[4.5]decyl, bicy-clo[2.2.1]heptyl, bicyclo[3.2.1]octyl, pinanyl, norbomyl, and bicyclo[2.2.2}octyl.
-9a-Benzocycloalkyl is typified by tetrahydronaphthyl, indanyl, and 1.2-benzocycloheptanyl.
Cycloalkoxy refers to a cycloalkyl group as just described, that is a monocycloalkyl, polycycloalkyl, or benzocycloalkyl structure, bound to the remainder of the molecule through an ethereal oxygen atom.

It will be appreciated that by the term "sulfone" is used in a generic sense to included not only compounds of Formula I in which R' is alkyl, phenyl, benzyl, but also the corresponding sulfonic acids when R' is hydroxy, and sulfonamides when R' is NR"R''.

A first preferred group of compounds are those of Formula I in which Y is C=O.
A further preferred group of compounds are those of Formula I in which Y is CHZ.

A further preferred group of compounds are those of Formula I in which each of R', R2, R', and R4 independently of the others, is hydrogen, halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or -NRgR9 in which each of Rg and R9 taken independently of the other is hydrogen or methyl. or one of R8 and R9 is hydrogen and the other is -COCH3.

A fiu-ther preferred group of compounds are those of Formula I in which one of R', RZ, R' and R" is -NHZ and the remaining of R', R2, R' and R4 are hydrogen.

A further preferred group of compounds are those of Formula I in which one of R', R2, R3, and R" is NHCOCH3 and the remaining of R, R2, R3 and R are hydrogen.

A further preferred group of compounds are those of Formula I in which one of R', R2, R3, and R4 is N(CH3)2 and the remaining of R', R2, R3 and R4 are hydrogen.
A further preferred group of compounds are those of Formula I in which one of R', R2, R3, and R4 is methyl and the remaining of R', R2, R3, and R4 are hydrogen.

A further preferred group of compounds are those of Formula I in which one of R', R2, R', and R4 is fluoro and the remaining of R', RZ, R3, and R are hydrogen.

A further preferred group of compounds are those of Formula I in which each of RS
and R6, independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.

A further preferred group of compounds are those of Formula I in which R5 is methoxy and R6 is monocycloalkoxy, polycycloalkoxy, and benzocycloalkoxy.

A further preferred group of compounds are those of Formula I in which RS is methoxy and Rb is ethoxy.

A further preferred group of compounds are those of Formula I in which R' is hydroxy, methyl, ethyl, phenyl, benzyl, or NRg'R9' in which each of RS' and R9' taken independently of the other is hydrogen or methyl.

A further preferred group of compounds are those of Formula I in which R' is methyl, ethyl, phenyl, benzyl or NRg'R9' in which each of R8' and R9' taken independently of the other is hydrogen or methyl.

A further preferred group of compounds are those of Formula I in which R' is methyl.

A further preferred group of compounds are those of Formula I in which R' is NR8'R9' in which each of RS' and R9' taken independently of the other is hydrogen or methyl.

The compounds of Formula I are used, under the supervision of qualified professionals, to inhibit the undesirable effects of TNFa and PDE IV. The compounds can be administered orally, rectally, or parenterally, alone or in combination with other therapeutic agents including antibiotics, steroids, etc., to a mammal in need of treatment.

The compounds also can be used topically in the treatment or prophylaxis of topical disease states mediated or exacerbated by excessive TNFa and PDE IV
production, respectively, such as viral infections, such as those caused by the herpes viruses, or viral conjunctivitis, psoriasis, atopic dermatitis, etc.

to The compounds also can be used in the veterinary treatment of mammals other than humans in need of prevention or inhibition of TNFa production. TNFa mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples include feline immunodeficiency virus, equine infectious anemia virus, caprine arthritis virus, visna virus, and maedi virus, as well as other lentiviruses.

In a first embodiment, the isoindolinone compounds of the present invention in which Y is C=0 can be prepared through reaction of an appropriately substituted phthalic anhydride and a substituted ethylamine:

~ + H2N-CI~ ~' Ri R6 N-CH

The two reagents are simply heated together, with or without a solvent, and the product isolated and purified by conventional means such as chromatography.
When one of R~, R2, R3, and R" is to be amino in the final sulfone, it often is desirable to utilize the corresponding nitro compound in the reaction of the phthalic anhydride and 5 substituted ethylamine and then catalytically convert the resulting nitroisoindolinone after formation. Alternatively, amino groups and other groups which may react can be converted to an appropriately protected group.

In a further embodiment, the isoindolinone compounds of the present invention in which Y is CH2 can be prepared through reaction of an appropriately substituted phthalic dicarboxaldehyde and a substituted ethylamine:

S
Ri R6 + H2N -CH ~-' R3 ~ CHO CH2-S02-R7 t N-CI~

Again the reagents need only be heated together, with or without a solvent, and the product isolated and purified by conventional means such as chromatography. As in the case of the phthalic anhydride used in the first embodiment, if one of R', RZ, R3 and R 4 is to be amino in the final sulfone, the corresponding nitro compound is used and the resulting nitroisoindolinone then catalytically reduced. Alternatively, one can employ an appropriately protected group, both for amino groups and for any other groups which may react.

Protecting groups utilized herein denote groups which generally are not found in the io final therapeutic compounds but which are intentionally introduced at some stage of the synthesis in order to protect groups which otherwise might be altered in the course of chemical manipulations. Such protecting groups are removed at a later stage of the synthesis and compounds bearing such protecting groups thus are of importance primarily as chemical intermediates (although some derivatives also exhibit biological activity). Accordingly the precise structure of the protecting group is not critical.
Numerous reactions for the formation and removal of such protecting groups are described in a number of standard works including, for example, "Protective Groups in Organic Chemistry", Plenum Press, London and New York, 1973; Greene, Th. W.
"Protective Groups in Organic Synthesis", Wiley, New York, 1981; "The Peptides", Vol. 1, Schroder and Lubke, Academic Press, London and New York, 1965;
"Methoden der organischen Chemie", Houben-Weyl, 4th Edition, Vol. 15/1, Georg Thieme Verlag, Stuttgart 1974.

An amino group can be protected as an amide utilizing an acyl group which is selectively removable under mild conditions, especially benzyloxycarbonyl, formyl, or a lower alkanoyl group which is branched in 1- or a-position to the carbonyl group, particularly tertiary alkanoyl such as pivaloyl, a lower alkanoyl group which is substituted in the position a to the carbonyl group, as for example trifluoroacetyl.

Coupling agents include such reagents as dicyclohexylcarbodimide and N,N
carbonyldiimidazole.

The compounds of Formula I possess a center of chirality and can exist as optical isomers. Both the racemates of these isomers and the individual isomers themselves, as well as diastereomers when there are two chiral centers, are within the scope of the present invention. The racemates can be used as such or can be separated into their individual isomers mechanically as by chromatography using a chiral absorbant.
Alternatively, the individual isomers can be prepared in chiral form or separated chemically from a mixture by forming salts with a chiral acid, such as the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, a-bromocamphoric acid, methoxyacetic acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, and the like, and then freeing one or both of the resolved bases, optionally repeating the process, so as obtain either or both substantially free of the other; i.e., in a form having an optical purity of >95%.

The present invention also pertains to the physiologically acceptable non-toxic acid addition salts of the compounds of Formula I. Such salts include those derived from organic and inorganic acids such as, without limitation, hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulphonic acid, acetic acid, tartaric acid, lactic acid, succinic acid, citric acid, malic acid, maleic acid, sorbic acid, aconitic acid, io salicylic acid, phthalic acid, embonic acid, enanthic acid, and the like.

Oral dosage forms include tablets, capsules, dragees, and similar shaped, compressed pharmaceutical forms containing from I to 100 mg of drug per unit dosage.
Isotonic saline solutions containing from 20 to 100 mg/mL can be used for parenteral administration which includes intramuscular, intrathecal, intravenous and intra-arterial routes of administration. Rectal administration can be effected through the use of suppositories formulated from conventional carriers such as cocoa butter.
Pharmaceutical compositions thus comprise one or more compounds of the present invention associated with at least one pharmaceutically acceptable carrier, diluent or excipient. In preparing such compositions, the active ingredients are usually mixed with or diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule or sachet. When the excipient serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, carrier, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders. Examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidinone, cellulose, water, syrup, and methyl cellulose, the formulations can additionally include lubricating agents such as talc, magnesium stearate and mineral oil, wetting agents, emulsifying and suspending agents, preserving agents such as methyl- and propylhydroxybenzoates, sweetening agents or flavoring agents.

The compositions preferably are formulated in unit dosage form, meaning physically discrete units suitable as a unitary dosage, or a predetermined fraction of a unitary dose l o to be administered in a single or multiple dosage regimen to human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient. The compositions can be formulated so as to provide an immediate, sustained or delayed release of active ingredient after administration to the patient by employing procedures well known in the art.

The following examples will serve to further typify the nature of this invention but should not be construed as a limitation in the scope thereof, which scope is defined solely by the appended claims.

Example 1 1-(3-Ethozy-4-metlioxyphenyl)-2-methylsutfonyledtylamine To a stirred solution of dimethyl sulfone (3.70 g, 39.4 mmol) in tetrahydrofuran (350 mL), was added n-butyllithium (17.5 mL, 2.5 M, 43.8 mmol) under nitrogen at -and the mixture was stirred at 78 C for 25 min. To a stirred solution of 3-ethoxy-4-methoxybenzaldehyde (7.10 g, 39.4 mmol) in tetrahydrofuran (40 mL) under nitrogen in a separate flask at 0 C was added lithium hexamethyldisilazide (43.0 mL, 1.0 M, 43.0 mmol) in hexane. After 15 min, boron trifluoride etherate (10.0 mL, 78.9 mmol) was added to the resulting mixture at 0 C. After 5 min, this solution was added to the -78 C sulfone solution via syringe. The solution was allowed to warm to room temperature over one hour. The resulting mixture was then quenched with potassium carbonate (32 g) and water (200 mL). The mixture was stirred for 30 min and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (3 X
200 mL). The combined organic layers were washed with water (50 mL), brine (50 mL), and then dried over magnesium sulfate. The solvent was removed in vacuo and the resulting solid stirred with ether (100 mL) and 4 N hydrochloric acid (100 mL) for 15 min. The aqueous layer was separated and the organic layer extracted with 4 N
hydrochloric acid (30 mL). The combined aqueous layers were washed with ether (50 mL), stirred, and cooled in an ice bath and the pH adjusted to 14 with sodium hydroxide (5 N). This solution was extracted with ethyl acetate (3 X 100 mL) and the combined organic layers were washed with brine (50 mL) and dried over sodium carbonate and sodium sulfate. Removal of solvent in vacuo gave an oil which was stirred with ether (20 mL) for 20 min to give a suspension. The suspension was filtered and the solid was washed with ether (20 mL) and then dried in a vacuum oven to yield 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine as an off-white solid (4.17 g, 39%): mp, 116.5-117.0 C; 'H NMR (CDC13) 6 1.47 (t, J= 7 Hz, 3H, CH3), 1.92 (br s 2H, NH2), 2.91 (s, 3H, SO2CH3), 3.19 (dd, J = 3.5, 14 Hz, 1H, CHH), 3.36 (dd, J =
9.3, 14 Hz IH, CHH), 3.87 (s, 3H, CH3), 4.10 (q, J=7 Hz, 2H, CH2), 4.60 (dd, J= 3.5, 9 Hz, IH, CH), 6.83-6.93 (m, 3H, Ar); 13C NMR (CDC13) S 14.75, 42.42, 50.94, 55.99, 63.18, 64.44, 110.71, 111.67, 118.21, 135.55, 148.72, 149.09; Anal Calcd for C,2Ht9N04S: C, 52.73; H, 7.01; N, 5.12. Found: C, 52.82; H, 6.69; N, 4.99.

Example 2 1-(3 Ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethylamine 1-(3 -Ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethylamine was pre-pared by a procedure analogous to that of Example 1 from N,N-dimethyl meth-anesulfonamide (685 mg, 5.56 mmol) and n-butyllithium (2.5 mL, 2.5 M, 6.3 mmol) in tetrahydrofuran (90 mL), and 3-ethoxy-4-methoxybenzaldehyde (1.0 g, 5.5 mmol), lithium hexamethyldisilazide (4.7 mL, 1.3 M, 6.1 mmol) and boron trifluoride etherate (1.4 mL, I1 mmol) in tetrahydrofuran (5 mL). The product was obtained as a white solid (360 mg, 21 % yield): mp, 82.0-83.0 C; 'H NMR (CDC 13); 8 1.48 (t, J=
7.5 Hz, to 3H, CH3), 1.91 (br s, 2H, NH2), 2.88 (s, 6H, N(CH3)2), 3.05 (dd, J = 3.0, 13.5 Hz, 1H, CHH), 3.12 (dd, J= 9.2, 13.5 Hz, 1 H, CHH), 3.88 (s, 3H, CH3), 4.12 (q, J= 7.0 Hz, 2H, CHz), 4.61 (dd, J = 2.9, 9.2 Hz, IH, NCH), 6.83-6.99 (m, 3H, Ar); "C NMR
(CDC13) S 14.81, 37.42, 51.02, 56.03, 64.41, 110.74, 111.55, 118.35, 135.97, 148.64, 148.96; Anal Calcd for C13H22NO4S: C, 51.64; H, 7.33; N, 9.26. Found: C, 51, 41; H, 7.11;N,9.10.
Example 3 2 (1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJisoindolin-l-one A stirred mixture 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (100 mg, 0.37 mmol) and 1,2-phthalic dicarboxaldehyde (49 mg, 0.37 mmol) in acetic acid (2 mL) was heated to reflux for 15 min. Removal of solvent in vacuo and chromatography gave an oil which was stirred with ether (2 mL). The resulting suspension was filtered to yield 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindolin-l-one as a light yellow solid (100 mg, 70%
yield): mp, 130.0-134.0 C; 'H NMR (CDC13) S 1.45 (t, J s = 7 Hz, 3H, CH3), 2.96 (s, 3H, CH3), 3.70 (dd, J= 4.5, 14.7, Hz, 1H, CHH), 3.86 (s, 3H, CH3), 4.07 (q, J= 6.9 Hz, 2H, CHZ), 4.25 (d, J= 16.5 Hz, I H, C HH), 4.31 (dd, J=10.3, 14.5 Hz, 1 H, CHR), 4.46 (d, J= 16 HZ, 1H, CHhI), 5.71 (dd, J= 4.5, 10.3 Hz, 1H, NCH), 6.84-7.01 (m, 3H, Ar), 7.38-7.56 (m, 3H, Ar), 7.85 (d, J= 6.9 Hz, IH, Ar); 13C NMR (CDC13) S 14.65, 41.33, 46.27, 52.33, 55.95, 56.00, 65.56, 111.45, 112.28, 119.30, 122.85, 123.85, 128.13, 129.89, 131.80, 132.27, 141.26, 148.88, 149.62, 169.09; Anal Calcd for C20H23 NOSS: C, 61.68; H, 5.95; N, 3.60. Found: C, 61.68, H, 6.06; N, 3.62.
Example 4 2 [1-(3-Ethoxy-4-metl:oxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethylJisoindolin-l-one 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethyl]isoindolin-1-one was prepared by the procedure of Example 3 from 1-(3-ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethylamine (150 mg, 0.49 mmol) and 1,2-phthalic dicarboxaldehyde (67 mg, 0.49 mmol) in acetic acid (2 mL). The product was obtained as a solid (142 mg, 69% yield): mp, 165.0-167.0 C; 'H NMR
(CDC13) S

1.45 (t, J= 7 Hz, 3H, CH3), 2.86 (s, 6H, N(CH3)2), 3.58 (dd, J = 4.7, 14.4 Hz, 1H, CHH), 3.86 (s, 3H, CH3), 4.08 (q, J= 7 Hz, 2H, CH2), 4.30 (d, J = 16.5 Hz, IH, NCHH), 4.33 (dd, J = 9, 14.4 Hz, 1 H, CHH), 4.49 (d, J = 16.5 Hz, 1 H, NCHH), 5.60 (dd, J= 4.7, 9.5 Hz, 1 H, NCH), 6.83 (d, J= 8.3 Hz, 1 H, Ar), 6.98 (dd, J= 2, 8.3 Hz, 1 H, Ar), 7.06 (d, J= 2Hz, 1 H, Ar), 7.37-7.56 (m, 3H, Ar), 7.84 (d, J = 7 Hz, 1 H, Ar), 13C NMR (CDC 1,) 8 14.69, 37.31, 48.64, 49.73, 52.91, 52.95, 64.54, 111.31, 112.46, 119.29, 122.76, 123.72, 128.03, 130.67, 131.55, 132.75, 141.26, 148.73, 149.39, 168.63; Anal Calcd for CZ,H26NOSS: C, 60.27; H, 6.26; N, 6.69. Found: C, 60.04; H, 6,10: N, 6.62.
Example 5 2 []-(3-Ethoxy-4-methoxyphenyl) 2-methylsufonylethylJisoindoline-1,.1-dione A mixture of 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (200 mg, 0.73 nunol) and sodium hydrogen carbonate (80 mg, 0.95 mmol) in acetonitrile and water(2 mL each) was stirred under nitrogen at room temperature for 2 minutes.
To the resulting solution was added N-ethoxycarbonylphthalimide (170 mg, 0.78 mmol).

After 17 hours, the resulting solution was stirred with hydrochloric acid (2 mL, 4 N), and water (30 mL) at room temperature for 30 minutes. The resulting suspension was filtered and the solid was washed with water (2 X 25 mL), and then dried in a vacuum oven overnight (60 C, < 1 torr) to yield 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3dione as a solid (206 mg, 70% yield): mp, 151.0-io 152.0 C; 'H NMR (CDC 13); 8 1.46 (t, J= 6.9 Hz, 3H, CH3), 2.84 (s, 311, CH,), 3.78 (dd, J= 4.8, 14.4 Hz, I H, CHH), 3.84 (s, 3H, CH3), 4.10 (q, J = 7 Hz, 2H, CHZ), 4.54 (dd, J = 10.1, 14.4 Hz, 1 H, CHH), 5.90 (dd, J= 4.8, 1 0.1 Hz, 1 H, NCH), 6.83 (d, J =
8.5 Hz, l H, Ar), 7.11-7.15 (m, 2H, Ar), 7.67-7.73 (m, 2H, Ar), 7.80-7.84 (m, 2H, Ar);
13C NMR (CDC13) S 14.63, 41.49, 48.84, 54.82, 55.89, 64.45, 111.43, 112.50, 120.43, 123.51, 129.56, 131.58, 134.17, 148.57,.149.63, 167.80; Anal Calcd for CZOHZ,NO6S:
C, 59.54; H, 5.25; N, 3.47. Found: C, 59.66; H, 5.28; N, 3.29.
Example 6 2-[]-(3-Ethoxy-4-methoxyphenyl)-2-met/tylsulfonyled:yl f-5-nitro-isoindoline-1,3-dione A stirred mixture of 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (1.0 g, 3.7 mmol) and 4-nitrophthalic anhydride (706 mg, 3.66 mmol) was heated to melt for 6 min. The mixture was allowed to cool to room temperature.
Chromatography of the resulting oil gave 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-nitro-isoindoline-1,3-dione as a solid (1.42 g, 87%
yield): mp, 255.0-256.0 C; 'H NMR (CDC13); S 1.47 (t, J= 7 Hz, 3H, CH3), 2.91 (s, 3H, CH3), 3.71 (dd, J= 4.2, 14.3 Hz, 1 H, CHH), 3.85 (2, 3H, CH3), 4.10 (q, J= 7 Hz, 2H, CH2), 4.59 (dd, J= 11.1, 14.1, Hz, 1H, CHH), 5.94 (dd, J= 4.1, 10.9 Hz, 1H, NCH), 6.82-6.86 (m, 2H, Ar), 7.09-7.14 (m, 2H, Ar), 8.01-8.04 (m, 1 H, Ar), 8.56-8.65 (m, 1 H, Ar), 13C NMR (CDC13) S 14.67, 41.61, 49.16, 53.99, 55.96, 64.54, 111.48, 112.39, 118.98, 120.48, 124.79, 128.73, 129.39, 133.06, 136.03, 148.71, 149.92, 151.79, 165.56, 165.74; Anal Calcd for C20HZONO8S: C, 53.57; H, 4.50; N, 6.23. Found: C, 53.59; H, 4.58; N, 5.88.
Example 7 2 [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsuljonylethylJ-S-aminoisoindoline-1,3-dione A mixture of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-nitro-iso-indoline-1,3-dione (600 mg, 1.33 mmol) and Pd/C (100 mg, 10%) in ethyl acetate (40 mL) was shaken under hydrogen (50 psi) for 7 h in Parr type shaker. The mixture was filtered through a pad of celite, and the pad was washed with ethyl acetate (50 mL).
The filtrate was concentrated in vacuo to give a solid. The solid was stirred in a mixture of methylene chloride (2 mL) and hexane (10 mL). The resulting suspension was filtered to give 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-aminoisoindoline-l,3-dione as a yellow solid (500 mg, 90% yield): mp, 224.5-227.0 C; 'H NMR (DMSO-d6); S 1.32 (t, J= 6.8 Hz, 3H, CH3), 2.99 (s, 3H, CH3), 3.73 (s, 3H, CH3), 3.73 (s, 3H, CH3), 4.00 (q, J= 7 Hz, 2H, CH2), 4.03-4.09 (m, 1 H, CHH), 2o 4.34 (dd, J= 10.3, 14.2 HZ, 1 H, CHH), 5.70 (dd, J= 3.7, 10.2 Hz, I H, NCH), 6.52 (br, s, 2H, NH2), 6.79-6.81 (m, 1 H, Ar), 6.92 (br s, 3H, Ar), 7.06 (br s, 1 H, Ar), 7.48 (d, J=
8.2 Hz, 1H, Ar); 13C NMR (DMSO-d6) S 14.64, 40.99, 46.99, 53.34, 55.46, 63.80, 106.99, 111.78, 112.31, 116.12, 116.80, 118.61, 125.12, 130.33, 134.11, 147.80, 148.74, 155.13, 167.39, 167.86; Anal Calcd for C20H2ZNO6S: 57.41; H, 5.30; N, 6.69.
Found: C, 57.03; H, 5.40; N, 6.33.

Example 8 2 []-(3 Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-4-nitroisoindoline-1,3-dione A stirred solution 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (640 mg, 2.34 mmol) and 3-nitrophthalic anhydride (460 mg, 2.34 mmol) in acetic acid (10 mL) was heated at reflux for 15 h. The solvent was removed in vacuo to yield an oil.
Chromatography of the resulting oil yielded 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-nitroisoindoline-1,3-dione as a yellow solid (850 mg, 81%
yield): mp, 110.0-114.0 C; 'H NMR (CDC 13); S 1.47 (t, J = 7.0 Hz, 3H, CH3), 2.90 (s, t o 3H, CH3), 3.71 (dd, J= 4.3, 14.4 Hz, 1 H, CHH), 3.85 (s, 3H, CH3), 4.10 (q, J= 7.0 Hz, 2H, CH2), 4.58 (dd, J= 10.7, 14.4 Hz, 1H, CHH), 5.93 (dd, J = 4.2, 10.7 Hz, IH, NCH), 6.84 (d, J= 8.8 Hz, 1 H, Ar), 7.11-7.15 (m, 2H, Ar), 7.89 (t, J= 7.8 Hz, 1 H, Ar), 8.08-8.13 (m, 2H, Ar); 13C NMR (CDC13) S 14.67, 41.56, 49.19, 53.97, 55.96, 64.56, 111.52, 112.51, 120.62, 123.44, 127.35, 128.65, 128.84, 133.73, 135.48, 145.24, 148.68, 149.92, 162.53, 165.33; Anal Calcd for C20HZONOBS: C, 53.57; H, 4.50;
N, 6.23. Found: C, 53.54; H, 4.28; N, 6.32 Example 9 2 [I-(3-Ethoxy-4-methoxyp/:enyl)-2-met/:ylsulfonylet/:y1J-4-aminoisoindoline-1,3-dione A mixture of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-nitroiso-indoline-1,3-dione (710 mg, 1.58 mmol) and Pd/C (200 mg) in ethyl acetate/acetone (40 mL each) was shaken under H2 (50 psi) in a Parr Type Shaker for 5 hours.
The suspension was filtered through a pad of magnesium sulfate. The filtrate was concentrated in vacuo to give an oil. The oil was stirred with ethyl acetate (a mL), hexane (2 mL) and ether (2ML)for 1 h. The resulting suspension was filtered and the solid was dried in a vacuum oven to give 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-l,3-dione as a yellow solid (550 mg, 83%

yield): mp, 135.0-137.5 C; 'H NMR (DMSO-d6); 8 1.32 (t, J= 6.9 Hz, 3H, CH3), 3.00 (s, 3H, CH3), 3.73 (s, 3H, CH3), 4.00 (q, J = 6.9 Hz, 2H, CH2), 4.08 (dd, J =
4.2, 14.5 Hz, 1 H, CHH), 4.36 (dd, J= 10.8, 14.2 Hz, 1 H, CHH), 5.72 (dd, J= 4.1, 10.3 Hz, 1 H, NCH), 6.51(br s, SH, NH2), 6.89-7.07 (m, 5H, Ar), 7.43 (t, J = 7.4, Hz, 1 H, Ar); 13C

NMR (CDC 1,) S 14.68, 41.55, 48.62, 55.23, 55.93, 64.48, 110.70, 111.42, 112.52, 112.96, 120.38, 121.30, 129.95, 132.23, 135.37, 145.56, 148.56, 149.56, 168.19, 169.43; Anal Calcd for CZOHZZNO6S: C, 57.41; H, 5.30; N, 6.69. Found C, 57.11;
H, 5.23; N, 6.43.
Example 10 2 [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-4-methyl-isoindoline-1,3-dione 2-[ 1-(3 -Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-methylisoindoline-1,3-dione was prepared by the procedure of Example 8 from I-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (1.4 g, 5.0 mmol) and 3-methylphthalic anhydride (810 mg, 5.0 mmol) in acetic acid (15 mL) to afford 2-[ 1-(3-ethoxy-methoxyphenyl)-2-methylsulfonylethylamine (1.0 g, 3.7 mmol) and 3-methylphthalic anhydride (590 mg, 3.7 mmol). The product was obtained as a white solid (1.78 g, 85%
yield); mp, 143.0-145.0 C; 'H NMR (CDC13) S 1.46 (t, J= 7.0 Hz, 3H, CH3), 2.67 (s, 3H, CH1), 2.83 (s, 3H, CH3), 3.79 (dd, J= 4.8, 14.5 Hz, 1H, CH-H), 3.85 (s, CH. CH1), 2o 4.11 (q, J = 7.0 Hz, 2H, CH2), 4.54 (dd, J= 9.8, 14.5 Hz, 1 H, CHH), 5.89 (dd, J = 4.8, 9.9Hz, 1 H, NCH), 6.81-6.85 (m, 1 H, Ar), 7.65 (d, J= 7.5 Hz, 1 H, Ar); ' 3C
NMR
(CDC13) S 14.65, 17.54, 41.49, 48.63, 54.89, 55.89, 64.44, 111.36, 112.48, 120.44, 121.17, 128.24, 129.69, 132.00, 133.69, 136.63, 138.29, 148.51, 149.55, 167.99, 168.46; Anal Calcd for C2,H23NO6S: C, 60.42; H, 5.55; N, 3.36. Found: C, 60.68; H, 5.40; N, 3.15.

____ Example 11 2 [1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-S-methyl-isoindoline-l,3-dione 2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-methylisoindoline-1,3-dione was prepared by the procedure of Example 6 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (1.0 g, 3.7 mmol) and 4-methylphythalic anhydride (590 mg, 3.7 mmol). The product was obtained as a white solid (710 mg, 46% yield): mp, 87.0-89.0 C; 'H NMR (CDC 13) S 1.45 (t, J= 7.0 Hz, 3H, CH,), 2.47 (s, 3H, CH3), 2.84 (s, 3H, CH3), 3.77-3.84 (m, 1H, CHH), 3.84 (s, 3H, CH3), 4.09 (q, J

l o = 7.0 Hz, 2H, CH2), 4.54 (dd, J= 10.2, 14.4 Hz, 1 H, CHH), 5.89 (dd, J=
4.7, 10.1 Hz, 1 H, NCH), 6.83 (d, J= 8.0 Hz, 1 H, Ar), 7.09-7.15 (m, 2H, Ar), 7.47 (d, J=
7.7 Hz, 1 H, Ar), 7.60 (s, 1 H, Ar), 7.67 (d, J= 7.6 Hz, 1 H, Ar); "C NMR (CDC13) S 14.51, 21.77, 41.31, 48.56, 54.59, 55.73, 64.26, 111.24, 112.31, 120.25, 123.26, 123.86, 128.81, 129.57, 131.79, 134.59, 145.43, 148.34, 149.36, 167.72, 167.87; Anal Calcd for C21H23N06S: C, 60.42; H, 5.55; N, 3.36. Found: C, 60.34; H, 5.49; N, 3.21.
Example 12 2 []-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-4-acetamido-isoindoline-1,3-dione 2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acedtamidoisoindoline-1,3-dione was prepared by the procedure of Example 8 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (1.0 g, 3.7 mmol) and 3-acetamidophthalic anhydride (751 mg, 3.66 mmol) in acetic acid (20 mL). The product was obtained as a yellow solid (1.0 g, 59% yield): mp, 144.0 C; 'H NMR
(CDC13) S
1.47 (t, J= 7.0 Hz, 3H, CH3), 2.26 (s, 3H, CH3), 2.88 (s, 3H, CH3), 3.75 (dd, J= 4.4, 14.3 Hz, 1 H, CHH), 5.87 (dd, J= 4.3, 10.5 Hz, 1 H, NCH), 6.82-6.86 (m, I H, Ar), 7.09-7.11 (m, 2H, Ar), 9.49 (br s, 1H, NH), "C NMR (CDC13) S 14.61, 24.85, 41.54, 48.44, 54.34, 55.85, 64.43, 111.37, 112.34, 115.04, 118.11, 120.21, 124.85, 129.17, 130.96, 136.01, 137.52, 148.54, 149.65, 167.38, 169.09, 169.40; Anal Calcd for CZZHz4N07S:
C, 57.38; H, 5.25; N, 6.08. Found: C, 57.31; H, 5.34; N, 5.83.
Example 13 2 []-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-S-acetamido-isoindoline-1,3-dione 2-[l-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5 -acetatnidoisoindoline-1,3-dione was prepared by the procedure of Example 6 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylainine (1.0 g, 3.7 mmol) and 4-acetamidophthalic anhydride (751 mg, 3.66 mmol). The product was obtained as a yellow solid (330 mg, 20% yield): mp, 215.0-217.0 C; 'H NMR (DMSO-d6) S 1.32 (t, J= 6.9 Hz, 3H, CH3), 2.12 (s, 3H, CH3), 2.99 (s, 3H, CH3), 3.73 (s, 3H, CH3), 4.00 (q, J
= 7.0 Hz, 2H, CH2), 4.12 (dd, J= 4.5, 14.3 Hz, 1 H, CHH), 4.35 (dd, J= 10.5, 14.2 Hz, 1 H, CHH), 5.76 (dd, J= 4.5, 10.5 Hz, 1 H, NCH), 6.90-6.98 (m, 2H, Ar), 7.08 (br s, 1 H, Ar), 7.83-7.84 (m, 2H, Ar), 8.19 (br s, IH, Ar), 10.95 (br s, IH, NH); 13C NMR

(DMSO-d6) S 14.66, 24.22, 41.05, 47.35, 53.07, 55.47, 63.80, 111.74, 112.28, 112.72, 123.34, 124.59, 124.66, 129.74, 132.68, 145.00, 147.85, 148.84, 167.00, 167.28, 169.36; Anal Calcd for CZZH24NO7S: C, 57.38; H, 5.25; N, 6.08. Found: C, 57.13; H, 5.18; N, 5.74.
Example 14 2 -11-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethylJ-4-dimethylamino isoindoline-1,3-dione 2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-dimethylaminoisoindo-line-l,3-dione was prepared by the procedure of Example 8 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (572 mg, 2.09 mmol) and 3-dimethylaminophthalic anhydride (400 mg, 2.09 mmol) in acetic acid (20 mL).
The product was obtained as a yellow solid (740 mg, 80% yield): mp, 94.0-96.0 C;
'H
NMR (CDC13) S 1.46 (t, J = 7.0 Hz, 3H, CH3), 2.82 (s, 3H, CH3), 3.08 (s, 6H, CH3), 3.76-3.84 (m, 1 H, CHH), 3.82 (s, 3H, CH3), 4.11 (q, J= 7.0 Hz, 2H, CH2), 4.54 (dd, J=
9.9, 14.5 Hz, IH, CHH), 5.88 (dd, J= 4.8, 9.9 Hz, 1 H, NCH), 6.81-6.84 (m, 1 H, Ar), 7.04-7.15 (m, 3H, Ar), 7.23-7.27 (m, IH, Ar), 7.48 (dd, J= 7.3, 8.3 Hz, IH, Ar); 13C
NMR (CDC 13) S 14.68, 41.47, 43.39, 48.74, 55.20, 55.92, 64.43, 111.34, 112.54, 113.78, 114.41, 120.47, 122.09, 129.97, 134.32, 134.81, 148.46, 149.44, 150.42, 167.06, 168.19; Anal Calcd for C22HZ6NO6S: C, 59.14; H, 5.91; N, 6.27. Found:
C, 59.14; H, 5.91; N, 6.10.
Example 15 2 [I-(3-Ethoxy-4-methoxypheny!)-2-methylsulfonylethylJ-5-dimethylamino-1 o isoindoline-1,3-dione 2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-dimethylaminoisoindoline-1,3-dione was prepared by the procedure of Example 8 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (572 mg, 2.09 mmol) and 4-dimethylaminophthalic anhydride (400 mg, 2.09 mmol) in acetic acid (20 mL).
The product was obtained as a yellow solid (200 mg, 21% yield): mp, 161.5-163.5 C; 'H
NMR (DMSO-d6) S 1.46 (t, J= 6.9 Hz, 3H, CH3), 2.79 (s, 3H, CH3), 3.09 (s, 6H, CH3), 3.78-3.85 (m, 1 H, CHH), 3.85 (s, 3H, CH3), 4.11 (q, J= 7.0 Hz, 2H, CH2), 4.51 (dd, J=
9.7, 14.6 Hz, 1 H, NCHH), 5.85 (dd, J= 5.1, 9.6 Hz, AH, NCH), 6.75-6.84 (m, 2H, Ar), 7.03 (d, J= 2.3 Hz, 1 H, Ar), 7.10-7.16 (m, 2H, Ar), 7.61 (d, J= 8.5 Hz, 1 H, Ar), "C

2o NMR (DMSO-d6) S 14.65, 40.40, 41.43, 48.83, 55.42, 55.89, 64.38, 105.80, 111.29, 112.43, 114.86, 116.90, 120.38, 125.11, 130.14, 134.27, 148.46, 149.38, 154.44, 168.14, 168.67; Anal Calcd for CzZHZ6NO6S + 0.2 H20: C, 58.70; H, 5.91; N, 6.22.
Found: C, 58.70; H, 5.93; N, 5.84.

~___ Example 16 2 -[]-(3-Ethoxy-4-methoxyphenyl)-2-methylsuffonylethylJbenzo[eJisoindoline-1,3-dione 2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]benzo[e]isoindoline-1,3-dione was prepared by the procedure of Example 8 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (1.31 g, 4.79 mmol) and 1,2-naphthalic anhydride (950 mg, 4.79 mmol) in acetic acid (15 mL). The product was obtained as a yellow solid (1.65 g, 76% yield): mp, 158.0-159.5 C; 'H NMR (DMSO-d6) S 1.33 (t, J
= 6.9 Hz, 3H, CH3), 3.03 (s, 3H, CH3), 3.73 (s, 3H, CH3), 4.03 (q, J= 6.9Hz, 2H, CH2), 4.18 (dd, J= 4.3, 14.3 Hz, 1 H, CHH), 4.41 (dd, J= 10.7, 14.4 Hz, 1 H, CHH), 5.86 (dd, J= 4.2, 10.3 Hz, 1 H, NCH), 6.83-6.96 (m, 1 H, Ar), 7.03-7.07 (m, 1 H, Ar), 7.15 (br s, 1 H, Ar), 7.70-7.90 (m, 3H, Ar), 8.15 (d, J= 8.0 Hz, 1 H, Ar), 8.39 (d, J= 8.3 Hz, 1 H, Ar), 8.76 (d, J = 8.2 Hz, 1H, Ar); "C NMR (DMSO-d6) S 19.86, 46.29, 52.48, 58.35, 60.67, 69.03, 116.96, 117.57, 123.65, 124.97, 128.97, 131.40, 132.30, 134.15, 134.36, 134.94, 135.16, 135.89, 140.85, 11.42, 153.09, 154.06, 173.09, 173.82; Anal Calcd for C24H23NO6S: C, 63.56; H, 5.11; N, 3.09. Found: C, 63.33; H, 5.06; N, 2.95.
Example 17 2 -1l-(3-Et/ioxy-4-methoxyphenyl)-2-methylsulfonylet/rylJ-4-methoxy-isoindoline-1,3-dione 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-methoxyisoindoline-1,3-dione was prepared by the procedure of Example 8 from 1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylamine (580 mg, 2.12 mmol) and 3-methoxyphthalic anhydride (380 mg, 2.13 mmol) in acetic acid (15 mL). The product was obtained as a white solid (620 mg, 67% yield): mp, 162.5-164.5 C; 'H NMR

(CDC13) S 1.45 (t,J= 6.9 Hz, 3H, CH,), 2.85 (s, 3H, CH,), 3.78 (dd,J= 4.7, 10.5 Hz, 1H, CHH), 3.84 (s, 3H, CH3), 3.99 (s, 3H, CH3), 4.09 (q, J = 6.9 Hz, 2H, CH2), 4.54 (dd, J= 10.3, 14.4 Hz, I H, CHH), 5.87 (dd, J= 4.6, 10.7 Hz, 1 H, NCH), 6.80-6.83 (m, 1 H, Ar), 7.10-7.18 (m, 3H, Ar), 7.38 (d, J= 7.3 Hz, 1 H, Ar), 7.63 (dd, J=
7.5, 8.2 Hz, 1H, Ar); "C NMR (CDC13) S 14.57, 41.32, 48.52, 54.62, 55.82, 56.19, 64.38, 111.35, 112.52, 115.56, 116.75, 117.58, 120.40, 129.58, 133.59, 136.30, 148.41, 149.46, 156.74, 166.43, 167.35; Anal Calcd for C21H23NO7S: C, 58.19; H, 5.35; N, 3.23.

Found: C, 58.05; H, 5.35; N, 3.24.
Example 18 Tablets, each containing 50 mg of 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yI)-4,5,6,7 tetrafluoroisoindoline, can be prepared in the following manner:

Constituents (for 1000 tablets) 2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]isoindolin-l-one........ 50.0 g lactose ................................ 50.7 g wheat starch ......................... 7.5 g polyethylene glycol 6000 .... 5.0 g talc ....................................... 5.0 g magnesium stearate ............. 1.8 g demineralized water ............ q.s.
The solid ingredients are first forced through a sieve of 0.6 mm mesh width.
The 2o active ingredient, lactose, talc, magnesium stearate and half of the starch then are mixed. The other half of the starch is suspended in 40 mL of water and this suspension is added to a boiling solution of the polyethylene glycol in 100 mL of water.
The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.

Example 19 Tablets, each containing 100 mg of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-(N,N-dimethylaminosulfonyl)ethyl]isoindolin- 1-one, can be prepared in the following manner:
Constituents (for 1000 tablets) 2-[ I -(3-ethoxy-4-methoxy-phenyl)-2-(N,N-dimethyl-aminosulfonyl)ethyl]-isoindolin-l-one .............. . 100.0 g lactose ..............................100.0 g wheat starch ....................... 47.0 g magnesium stearate ............. 3.0 g All the solid ingredients are first forced through a sieve of 0.6 mm mesh width. The active ingredient, lactose, magnesium stearate and half of the starch then are mixed.
The other half of the starch is suspended in 40 mL of water and this suspension is added to 100 mL of boiling water. The resulting paste is added to the pulverulent substances and the mixture is granulated, if necessary with the addition of water. The granulate is dried overnight at 35 C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 6 mm diameter which are concave on both sides.
Example 20 Tablets for chewing, each containing 75 mg of 2-[1-(3-ethoxy-4-methoxyphenyl)-methylsulfonylethyI]isoindoline-1,3-dione, can be prepared in the following manner:
Composition (for 1000 tablets) 2-[l -(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]isoindoline- 1,3-dione75.0 g mannitol .......................... 230.09 lactose .............................. 150.0 g talc ..................................... 21.0 g glycine ............................... 12.5 g stearic acid ......................... 10.0 g saccharin .............................. 1.5 g 5% gelatin solution .............. q.s.

All the solid ingredients are first forced through a sieve of 0.25 mm mesh width.
The mannitol and the lactose are mixed, granulated with the addition of gelatin solution, forced through a sieve of 2 mm mesh width, dried at 50 C and again forced through a sieve of 1.7 mm mesh width. 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3-dione, the glycine and the saccharin are carefully mixed, the mannitol, the lactose granulate, the stearic acid and the talc are added and the whole is mixed thoroughly and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking groove on the upper side.
Example 21 Tablets, each containing 10 mg of 2-(2,6-dioxoethylpiperidin-3-yl)-4-aminophthalimide, can be prepared in the following manner:
Comaosition (for 1000 tablets) 2-[ 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-5-nitro-isoindoline-1,3-dione ............................ 10.0 g lactose .............................. 328.5 g corn starch ......................... 17.5 g polyethylene glycol 6000.... 5.0 g talc ..................................... 25.0 g magnesium stearate ............. 4.0 g demineralized water ............ q.s.
The solid ingredients are first forced through a sieve of 0.6 mm mesh width.
Then the active ingredient, lactose, talc, magnesium stearate and half of the starch are intimately mixed. The other half of the starch is suspended in 65 mL of water and this suspension is added to a boiling solution of the polyethylene glycol in 260 mL
of water.
The resulting paste is added to the pulverulent substances, and the whole is mixed and granulated, if necessary with the addition of water. The granulate is dried overnight at 3o 35 C, forced through a sieve of 1.2 mm mesh width and compressed to form tablets of approximately 10 mm diameter which are concave on both sides and have a breaking notch on the upper side.
Example 22 Gelatin dry-filled capsules, each containing 100 mg of 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-l,3-dione, can be prepared in the following manner:
Composition (for 1000 capsules) 2-[1-(3-ethoxy-4-methoxy-phenyl )-2 -methyl sul fonyl -ethyl]-4-aminoisoindoline-1,3-dione .......................... 100.0 g microcrystalline cel lulose...... .30.0 g sodium lauryl sulfate ........... 2.0 g magnesium stearate ............. 8.Og The sodium lauryl sulfate is sieved into the 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-1,3-dione through a sieve of 0.2 mm mesh width and the two components are intimately mixed for 10 minutes. The microcrystalline cellulose is then added through a sieve of 0.9 mm mesh width and the whole is again intimately mixed for 10 minutes. Finally, the magnesium stearate is added through a sieve of 0.8 mm width and, after mixing for a further 3 minutes, the mixture is introduced in portions of 140 mg each into size 0 (elongated) gelatin dry-fill capsules.
Example 23 A 0.2% injection or infusion solution can be prepared, for example, in the following manner:
2-[ l -(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-4-arninoisoindoline-1,3-dione hydrochloride ...... 5.0 g sodium chloride ..................... .22.5 g phosphate buffer pH 7.4.. 300.0 g demineralized water.. to 2500.0 mL
2-[ 1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-1,3-dioxoisoindoline as the hydrochloride is dissolved in 1000 mL of water and filtered through a microfilter. The buffer solution is added and the whole is made up to 2500 mL with water. To prepare dosage unit forms, portions of 1.0 or 2.5 mL each are introduced into glass ampoules (each containing respectively 2.0 or 5.0 mg of active ingredient).

Claims (34)

CLAIMS:
1. A sulfone selected from:

(a) a compound of the formula:
in which:

the carbon atom designated * constitutes a center of chirality;
Y is C=O, CH2, SO2 or CH2C=O;

each of R1, R2, R3, and R4, independently of the others, is hydrogen, halo, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, nitro, cyano.
hydroxy, or -NR8R9; or any two of R1, R2, R3, and R4 on adjacent carbon atoms, together with the depicted phenylene ring are naphthylidene each of R5 and R6, independently of the other, is hydrogen, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, or cycloalkoxy of up to 18 carbon atoms;

R7 is hydroxy, alkyl of 1 to 8 carbon atoms, phenyl, benzyl, or NR8R9;

each of R8 and R9 taken independently of the other is hydrogen, alkyl of 1 to carbon atoms, phenyl, or benzyl, or one of R8 and R9 is hydrogen and the other is -COR10, -SO2R10, or -NH COR10, or R8 and R9 taken together are tetramethylene, pentamethylene, hexamethylene, or - -H2CH2X1 2CH2 in which X1 is -O-, -S- or -NH-;

each of R8* and R9* taken independently of the other is hydrogen, alkyl of 1 to 8 carbon atoms, phenyl, or benzyl, or one of R8* and R9* is hydrogen and the other is -COR10*, -SO2R10*, or -NHCOR10*, or R8* and R9* taken together are tetramethylene, pentamethylene, hexamethylene, or -CH2CH2X2CH2CH2- in which X2 is -O-, =S- or -NH-;

R10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and R10* is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and (b) the acid addition salts of said compounds which contain a nitrogen atom susceptible of protonation.
2. A sulfone according to claim 1 wherein in said sulfone, Y is C=O.
3. A sulfone according to claim 1 wherein in said sulfone, Y is CH2.
4. A sulfone according to claim 1 wherein in said sulfone, each of R1, R2, R3, and R4, independently of the others, is hydrogen, -halo, methyl, ethyl, methoxy, ethoxy, nitro, cyano, hydroxy, or -NR8R9 in which each of R8 and R9 taken independently of the other is hydrogen or methyl, or one of R8* and R9* is hydrogen and -the other is -COCH3.
5. A sulfone according to claim 1 wherein in said sulfone, one of R1, R2, R3, and R4 is -NH2 and the remaining of R1, R2, R3 and R4 is hydrogen.
6. A sulfone according to claim 1 wherein in said sulfone, one of R1, R2, R3, and R4 is -NHCOCH3 and the remaining of R1, R2, R3, and R4 is hydrogen.
7. A sulfone according to claim 1 wherein in said sulfone, one of R1, R2, R3, and R4 is methyl and the remaining of R1, R2, R3, and R4 is hydrogen.
8. A sulfone according to claim 1 wherein in said sulfone, one of R1, R2, R3 and R4 is fluoro and the remaining of R1, R2, R3 and R4 is hydrogen.
9. A sulfone according to claim 1 wherein in said sulfone, each of R5 and R6, independently of the other, is hydrogen, methyl, ethyl, propyl, methoxy, ethoxy, propoxy, cyclopentoxy, or cyclohexoxy.
10. A sulfone according to claim 1 wherein in said sulfone, R5 is methoxy and R6 is ethoxy.
11. A sulfone according to claim 1 wherein in said sulfone, R7 is hydroxy, methyl, ethyl, phenyl, benzyl, or NR8*9* in which each of R8* and R9* taken independently of the other is hydrogen or methyl.
12. A sulfone according to claim 1 wherein in said sulfone, R7 is methyl, ethyl, phenyl, benzyl, or NR8*R9* in which each of R8* and R9* taken independently of the other is hydrogen or methyl.
13. A sulfone according to claim 1 wherein in said sulfone, R7 is methyl.
14. A sulfone according to claim 1 wherein in said sulfone , R7 is NR8'R9' in which each of R8' and R9' taken independently of the other is hydrogen or methyl.
15. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methyl-sulfonylethyl]isoindolin-1-one.
16. A sulfone according to claim 1 which is 2[1-(3-ethoxy-4-methoxyphenyl)-2-(N,N-dimethyl-aminosulfonyl)ethyl]isoindolin-1-one.
17. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methyl-sulfonylethyl]isoindoline-1,3-dione.
18. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methyl-sulfonylethyl]-5-nitroisoindoline-1,3-dione.
19. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methyl-sulfonylethyl]-4-nitroisoindoline-1,3-dione.
20. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-1,3-dione.
21. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-methylisoindoline-1,3-dione.
22. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-acetamidoisoindoline-1,3-dione.
23. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetamidoisoindoline-1,3-dione.
24. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-dimethylaminoisoindoline-1,3-dione.
25. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-5-dimethylaminoisoindoline-1,3-dione.
26. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]benzo[e]isoindoline-1,3-dione.
27. A sulfone according to claim 1 which is 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-methoxyisoindoline-1,3-dione.
28. A pharmaceutical composition comprising an effective amount of the sulfone as defined in any one of claims 1 to 27 and a carrier, for reducing undesirable levels of TNF.alpha. in a mammal.
29. A pharmaceutical composition comprising an effective amount of the sulfone as defined in any one of claims 1 to 27 and a carrier, for inhibiting PDE IV in a mammal.
30. Use of an effective amount of the sulfone as defined in any one of claims 1 to 27 in the manufacture of a medicament for reducing undesirable levels of TNF.alpha. in a mammal.
31. Use of an effective amount of the sulfone as defined in any one of claims 1 to 27 for reducing undesirable levels of TNF.alpha. in a mammal.
32. Use of an effective amount of the sulfone as defined in any one of claims 1 to 27 in the manufacture of a medicament for inhibiting PDE IV in a mammal.
33. Use of an effective amount of the sulfone as defined in any one of claims 1 to 27 for inhibiting PDE IV
in a mammal.
34. A pharmaceutical composition comprising a quantity of the sulfone as defined in any one of claims 1 to 27 sufficient upon administration in a single or multiple dose regimen to reduce levels of TNF.alpha. in a mammal in combination with a carrier.
CA002348993A 1998-10-30 1999-10-19 Substituted phenethylsulfones and method of reducing tnf.alpha. levels Expired - Fee Related CA2348993C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/183,049 US6020358A (en) 1998-10-30 1998-10-30 Substituted phenethylsulfones and method of reducing TNFα levels
US09/183,049 1998-10-30
PCT/US1999/024376 WO2000025777A1 (en) 1998-10-30 1999-10-19 SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS

Publications (2)

Publication Number Publication Date
CA2348993A1 CA2348993A1 (en) 2000-05-11
CA2348993C true CA2348993C (en) 2009-12-29

Family

ID=22671217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002348993A Expired - Fee Related CA2348993C (en) 1998-10-30 1999-10-19 Substituted phenethylsulfones and method of reducing tnf.alpha. levels

Country Status (16)

Country Link
US (2) US6020358A (en)
EP (3) EP2305248B1 (en)
JP (1) JP4530543B2 (en)
AT (2) ATE471718T1 (en)
AU (1) AU756308B2 (en)
BR (2) BRPI9915201B8 (en)
CA (1) CA2348993C (en)
CY (3) CY1107499T1 (en)
DE (2) DE69934708T2 (en)
DK (3) DK2305248T3 (en)
ES (3) ES2421153T3 (en)
HK (2) HK1038696B (en)
NO (1) NO319790B1 (en)
NZ (1) NZ511253A (en)
PT (3) PT2305248E (en)
WO (1) WO2000025777A1 (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP0918746B1 (en) * 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutic agents and their use in the reduction of cytokine levels
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6699899B1 (en) * 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
EP1272189A4 (en) * 2000-03-31 2004-01-14 Celgene Corp Inhibition of cyclooxygenase-2 activity
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
ES2290091T3 (en) * 2000-11-30 2008-02-16 The Children's Medical Center Corporation SYNTHESIS OF ENANTIOMERS OF 4-AMINO-TALIDOMIDE.
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
WO2003080048A1 (en) * 2002-03-20 2003-10-02 Celgene Corporation (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CN1965823B (en) * 2002-03-20 2010-05-12 细胞基因公司 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione, its preparation method and its compound
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN1658848A (en) 2002-04-12 2005-08-24 细胞基因公司 Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
CA2481385A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
CA2672000C (en) * 2002-05-17 2011-11-29 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2491614A1 (en) * 2002-07-02 2004-01-15 Qlt Inc. Compounds and methods for treating cancer and inflammation
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
EP1551385A4 (en) * 2002-10-15 2008-10-22 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
JP2006509743A (en) * 2002-10-31 2006-03-23 セルジーン・コーポレーション Methods of using selective cytokine inhibitors for the treatment and management of macular degeneration and compositions containing the same
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
KR20090048520A (en) 2002-11-06 2009-05-13 셀진 코포레이션 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2004043336A2 (en) * 2002-11-06 2004-05-27 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
NZ540546A (en) * 2002-11-18 2008-03-28 Celgene Corp Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
JP2006510617A (en) * 2002-11-18 2006-03-30 セルジーン・コーポレーション Method of using (+)-3- (3,4-dimethoxy-phenyl) -3- (1-oxo-1,3-dihydro-isoindol-2-yl) -propionamide and compositions containing it
US7173058B2 (en) * 2002-12-30 2007-02-06 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
AU2004216813B2 (en) * 2003-03-03 2008-09-11 F. Hoffmann-La Roche Ag 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-HT6 modulators
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
ZA200507322B (en) * 2003-03-06 2007-03-28 Celgene Corp Selective cytokine inhibitory drugs for treating disorders of the central nervous system
US7034052B2 (en) 2003-03-12 2006-04-25 Celgene Corporation 7-Amido-isoindolyl compounds and their pharmaceutical uses
MXPA05013975A (en) * 2003-06-23 2006-03-09 Neurochem Int Ltd Treatment of amyloid- and epileptogenesis-associated diseases.
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2007524656A (en) * 2003-10-23 2007-08-30 セルジーン・コーポレーション Compositions comprising selective cytokine inhibitors for treating, modifying and managing pain and methods of use thereof
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CA2545128C (en) * 2003-11-06 2010-01-12 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
JP2007511618A (en) 2003-11-19 2007-05-10 シグナル ファーマシューティカルズ,エルエルシー Indazole compounds and methods of use as protein kinase inhibitors
CN101966183A (en) * 2003-12-02 2011-02-09 细胞基因公司 Methods and compositions for the treatment and management of hemoglobinopathy and anemia
JP2007532641A (en) * 2004-04-14 2007-11-15 セルジーン・コーポレーション Use of immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and compositions comprising the same
WO2005110085A2 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
MXPA06012279A (en) * 2004-04-23 2007-01-31 Celgene Corp Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension.
WO2005112917A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006050057A2 (en) 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
EP1838294A1 (en) * 2004-12-13 2007-10-03 Celgene Corporation Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
TW200804347A (en) * 2006-01-10 2008-01-16 Janssen Pharmaceutica Nv Urotensin II receptor antagonists
CN101522197B (en) 2006-07-31 2013-12-11 詹森药业有限公司 Urotensin II receptor antagonists
CL2007002218A1 (en) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA.
PA8782701A1 (en) 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv UROTENSIN II RECEIVER ANTAGONISTS
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
MX2010010334A (en) * 2008-03-24 2010-10-08 Celgene Corp Treatment of psoriasis or psoriatic arthritis using cyclopropyl-n-{2-{(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsu lfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide.
MX359839B (en) 2008-03-27 2018-10-12 Celgene Corp Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-meth ylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof.
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
ATE546448T1 (en) * 2008-08-02 2012-03-15 Janssen Pharmaceutica Nv UROTENSIN II RECEPTOR ANTAGONISTS
JP5513508B2 (en) * 2008-09-10 2014-06-04 セルジーン コーポレイション Process for preparing aminosulfone compounds
SG173149A1 (en) 2009-02-10 2011-08-29 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
ES2441740T3 (en) * 2009-05-14 2014-02-06 Tianjin Hemay Bio-Tech Co., Ltd. Thiophene derivatives
EP2443089B1 (en) * 2009-06-18 2014-03-05 Concert Pharmaceuticals Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
WO2011044479A1 (en) 2009-10-09 2011-04-14 Celgene Corporation Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
CA2798742A1 (en) 2010-06-15 2011-12-22 Celgene Corporation Biomarkers for the treatment of psoriasis
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
CN102558022B (en) * 2010-12-22 2016-06-15 康塞特医药品有限公司 Isoindoline-1,3 derovatives replaced
MX347928B (en) * 2011-01-10 2017-05-19 Celgene Corp Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines.
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
EP3320902B1 (en) 2011-03-07 2021-02-17 Amgen (Europe) GmbH Methods for treating diseases using isoindoline compounds
EP2701701B1 (en) 2011-04-28 2018-01-24 Celgene Corporation Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
EP2797581B1 (en) * 2011-12-27 2020-05-06 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
AR090100A1 (en) 2012-02-21 2014-10-22 Celgene Corp PROCESSES FOR THE PREPARATION OF (S) -1- (3-ETOXI-4-METOXIFENIL) -2-METHANOSULPHONILETILAMINE
EP2730278A1 (en) 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
BR112015020584A2 (en) 2013-03-14 2017-07-18 Celgene Corp Methods for treating psoriatic arthritis using apremilast
EP3010490A1 (en) 2013-06-17 2016-04-27 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (en) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
EP3143004B1 (en) 2014-05-11 2020-09-02 Mapi Pharma Limited Amorphous form of apremilast
ES2751773T3 (en) 2014-05-15 2020-04-01 Amgen Europe Gmbh Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016025686A1 (en) 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
EA201790439A1 (en) 2014-08-22 2017-07-31 Селджин Корпорейшн METHODS OF TREATING MULTIPLE MYELOMA WITH THE USE OF IMMUNOMODULATING COMPOUNDS IN COMBINATION WITH ANTIBODIES
CN105461610B (en) * 2014-09-10 2018-04-13 杭州普晒医药科技有限公司 A kind of crystal form of Apremilast and preparation method thereof, pharmaceutical composition and purposes
CN104761484B (en) * 2014-11-24 2018-03-27 上海优拓医药科技有限公司 A kind of A Pusite crystal formations II without solvate of stabilization and preparation method thereof
CN104496886A (en) * 2014-12-11 2015-04-08 杭州新博思生物医药有限公司 Preparation method of high-purity apremilast B crystal form
EP3271330A1 (en) 2015-03-19 2018-01-24 Cipla Limited Improved process for the preparation of apremilast
WO2016161996A1 (en) 2015-04-09 2016-10-13 Zentiva, K.S. A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
WO2016169533A1 (en) 2015-04-24 2016-10-27 Zentiva, K.S. A solid form of apremilast and a process for preparing the same
US10370329B2 (en) * 2015-04-27 2019-08-06 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
CN104945306B (en) * 2015-05-25 2017-07-21 山东铭康医药技术有限公司 The method for preparing optical voidness Apremilast
CZ2015383A3 (en) 2015-06-05 2016-12-14 Zentiva, K.S. Process for preparing apremilast key intermediate employing enzymatic cleavage of racemic amines
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
WO2016210262A1 (en) 2015-06-26 2016-12-29 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
US10399942B2 (en) 2015-11-19 2019-09-03 Alembic Pharmaceuticals Limited Process and novel polymorphic form of Apremilast
CN105294533A (en) * 2015-12-02 2016-02-03 宋彤云 Pharmaceutical composition for treating bone diseases
WO2017179065A1 (en) 2016-04-15 2017-10-19 Davuluri Ramamohan Rao Improved process for the preparation of apremilast
CN109310624A (en) 2016-06-15 2019-02-05 托伦特药物有限公司 The topical composition of Apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (en) * 2016-09-28 2018-04-10 中南大学湘雅医院 A kind of synthesis technique of Apremilast intermediate
NZ756231A (en) 2017-02-28 2021-12-24 Kangpu Biopharmaceuticals Ltd A novel isoindoline derivative, a pharmaceutical composition and use thereof
SI3606908T1 (en) * 2017-04-04 2020-10-30 Quimica Sintetica, S.A. Resolution of racemic beta-aminosulfone compounds
ES2866476T3 (en) 2017-04-04 2021-10-19 Quim Sintetica S A Racemic beta-aminosulfone compounds
WO2018203192A1 (en) 2017-05-04 2018-11-08 Unichem Laboratories Ltd Novel process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4-yl]acetamide
CN109422671B (en) * 2017-08-31 2022-06-07 重庆医药工业研究院有限责任公司 Preparation method of apremilast intermediate
US20200254093A1 (en) 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP7196169B2 (en) 2017-10-23 2022-12-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel combinations of active agents for the treatment of interstitial lung disease with progressive fibrosis (PF-ILD)
WO2019142124A1 (en) 2018-01-17 2019-07-25 Cadila Healthcare Limited Pharmaceutical compositions for treatment of vitiligo
CA3098927C (en) 2018-05-02 2023-10-03 Donglei ZHANG Crystal forms of thiophene derivatives
CN110746376A (en) * 2018-07-22 2020-02-04 上海星叶医药科技有限公司 Benzoisoselenazolone amine compound and preparation method and application thereof
CN110423213B (en) * 2019-08-22 2021-06-04 上海英诺富成生物科技有限公司 Apremilast derivative and preparation method and application thereof
EP3929179A1 (en) 2020-06-22 2021-12-29 Biohorm, S.L. Anti-inflammatory compounds and methods for their manufacture
CN114790164B (en) 2021-08-13 2022-12-27 苏州璞正医药有限公司 Substituted isoindoline-1,3-diketone PDE4 inhibitor and pharmaceutical application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) * 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (en) * 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab NEW THERAPEUTIC WORLDFUL TAURIN DERIVATIVES AND THEIR PREPARATION
US4820828A (en) * 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
ATE197038T1 (en) * 1995-07-26 2000-11-15 Pfizer N-AROYL-GLYCINE HYDROXAMIC ACID DERIVATIVES AND RELATED COMPOUNDS
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
ATE262899T1 (en) * 1996-01-02 2004-04-15 Aventis Pharma Inc SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIZAEUR COMPOUNDS

Also Published As

Publication number Publication date
DK2305248T3 (en) 2013-07-29
NO319790B1 (en) 2005-09-12
DE69934708T2 (en) 2007-10-18
WO2000025777A1 (en) 2000-05-11
HK1103224A1 (en) 2007-12-14
PT2305248E (en) 2013-08-22
PT1126839E (en) 2007-03-30
DE69934708D1 (en) 2007-02-15
JP2002528496A (en) 2002-09-03
US6020358A (en) 2000-02-01
EP1752148A2 (en) 2007-02-14
ATE471718T1 (en) 2010-07-15
DK1752148T3 (en) 2010-09-27
HK1038696A1 (en) 2002-03-28
BRPI9915201B8 (en) 2021-07-06
CY1107499T1 (en) 2013-03-13
EP1126839B1 (en) 2007-01-03
BRPI9915201A (en) 2001-10-30
EP1752148A3 (en) 2007-03-14
ES2343744T3 (en) 2010-08-09
DK1126839T3 (en) 2007-05-14
JP4530543B2 (en) 2010-08-25
CY1114304T1 (en) 2016-08-31
NO20012021L (en) 2001-06-26
ATE350033T1 (en) 2007-01-15
ES2421153T3 (en) 2013-08-29
AU756308B2 (en) 2003-01-09
ES2278467T3 (en) 2007-08-01
HK1038696B (en) 2007-08-03
BRPI9915201B1 (en) 2012-02-22
EP1126839A4 (en) 2004-10-27
PT1752148E (en) 2010-09-28
US6011050A (en) 2000-01-04
NZ511253A (en) 2003-02-28
NO20012021D0 (en) 2001-04-24
EP1126839A1 (en) 2001-08-29
EP2305248B1 (en) 2013-05-08
EP1752148B1 (en) 2010-06-23
AU1447200A (en) 2000-05-22
DE69942532D1 (en) 2010-08-05
CA2348993A1 (en) 2000-05-11
CY1110752T1 (en) 2015-06-10
EP2305248A1 (en) 2011-04-06
BR9915201A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
CA2348993C (en) Substituted phenethylsulfones and method of reducing tnf.alpha. levels
EP1462449B9 (en) Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels
US6214857B1 (en) Substituted alkanohydroxamic acids and method of reducing TNFα levels
US6403613B1 (en) 1-oxo-and 1,3-dioxoisoindolines
US7459466B2 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNFα levels
US5798368A (en) Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2317834C (en) Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce tnf.alpha. levels
AU2006200033B2 (en) Substituted phenethylsulfones and methods of reducing TNF-alpha levels
AU2003203681B2 (en) Substituted phenethylsulfones and methods of reducing TNF-alpha-levels
MXPA00001018A (en) SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF&amp;agr;LEVELS
MXPA00008645A (en) 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141020